Impact of shifting from routine use of ticagrelor to prasugrel in myocardial infarction patients after PCI: a nationwide cohort study
A shift from ticagrelor to prasugrel occurred between 2019 and 2022 among real-world MI patients post-PCI. Prasugrel was associated with reduced rates of MACE and MI and with similar bleeding rates compared with ticagrelor, supporting current guideline recommendations.
Authors
- Erik Lerkevang Grove (ORCID: https://orcid.org/0000-0002-1466-0865)
- Mia Ravn Jacobsen (ORCID: https://orcid.org/0000-0002-3990-4176)
- Lars Køber (ORCID: https://orcid.org/0000-0002-6635-1466)
- Peter Laursen Graversen (ORCID: https://orcid.org/0000-0003-1231-6283)
- Reza Jabbari (ORCID: https://orcid.org/0000-0001-7835-3840)
- Thomas Engstrøm (ORCID: https://orcid.org/0000-0001-5436-9194)
- Rikke Sørensen (ORCID: https://orcid.org/0000-0001-9238-6681)
- Charlotte Glinge (ORCID: https://orcid.org/0000-0003-0406-256X)
- Tobias Geisler (ORCID: https://orcid.org/0000-0002-8864-6038)
- Lene Holmvang
- Christian Torp-Pedersen
Institutions
- Aarhus University (DK)
- Aarhus University Hospital (DK)
- Copenhagen University Hospital (DK)
- Nordsjællands Hospital (DK)
Publication Details
- Journal
- EuroIntervention
- Published
- 2025-10-28
- DOI
- https://doi.org/10.4244/eij-d-25-00132
- Primary Topic
- Antiplatelet Therapy and Cardiovascular Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00